Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.77 |
| ▸ | MAOA | P21397 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | ACHE | P22303 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209619 | 0.95 | CYP3A4 (0.81) | MAOBMAOACYP3A4CYP1A2CYP2E1 | |
| SCHEMBL4217923 | 0.90 | MAOA (0.63) | MAOBMAOA | |
| SCHEMBL4208266 | 0.90 | MAOB (0.63) | MAOBMAOACYP3A4ACHE | |
| SCHEMBL4211340 | 0.89 | MAOB (0.62) | MAOBMAOACYP3A4ACHE | |
| SCHEMBL4211604 | 0.88 | MAOB (0.62) | MAOBMAOACYP3A4ACHE | |
| SCHEMBL4208371 | 0.87 | MAOA (1.00) | MAOBMAOACYP3A4CYP1A2CYP2E1 | |
| SCHEMBL4208125 | 0.86 | MAOB (0.77) | MAOBCYP3A4ACHE | |
| SCHEMBL4210992 | 0.86 | CYP19A1 (0.66) | MAOBCYP3A4ACHE | |
| SCHEMBL4213219 | 0.86 | CYP19A1 (0.66) | MAOBCYP3A4ACHE | |
| SCHEMBL4211629 | 0.84 | CYP3A4 (0.61) | MAOBCYP3A4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005436-A1 | Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-01-01 | — | — | US | claimed |
| EP-1863784-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2007-12-12 | — | — | EP | claimed |
| WO-2006102958-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2006-10-05 | — | — | WO | claimed |
| US-20090005436-A1 | Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-01-01 | — | — | US | disclosed |
| EP-1863784-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006102958-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005436-A1 | Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives | MAOB, MAOA, AOC3 | MAOB 1/4885MAOA 2/4885CYP3A4 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.